Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-013960
Filing Date
2024-10-30
Accepted
2024-10-30 16:27:49
Documents
108
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bpmc-20240930x10q.htm   iXBRL 10-Q 3131145
2 EX-31.1 bpmc-20240930xex31d1.htm EX-31.1 11340
3 EX-31.2 bpmc-20240930xex31d2.htm EX-31.2 11411
4 EX-32.1 bpmc-20240930xex32d1.htm EX-32.1 10876
  Complete submission text file 0001558370-24-013960.txt   11766157

Data Files

Seq Description Document Type Size
5 EX-101.SCH bpmc-20240930.xsd EX-101.SCH 85982
6 EX-101.CAL bpmc-20240930_cal.xml EX-101.CAL 75486
7 EX-101.DEF bpmc-20240930_def.xml EX-101.DEF 343854
8 EX-101.LAB bpmc-20240930_lab.xml EX-101.LAB 658639
9 EX-101.PRE bpmc-20240930_pre.xml EX-101.PRE 581231
111 EXTRACTED XBRL INSTANCE DOCUMENT bpmc-20240930x10q_htm.xml XML 2039367
Mailing Address 45 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 45 SIDNEY STREET CAMBRIDGE MA 02139 617-374-7580
Blueprint Medicines Corp (Filer) CIK: 0001597264 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37359 | Film No.: 241410756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)